#United States #LYNX #Norlase #Ophthalmoscope #Redwood City, California

Norlase Introduces Groundbreaking LYNX™ Laser Indirect Ophthalmoscope

Norlase, a leading manufacturer of ophthalmic lasers, has made headlines with its recent approval from the FDA and CE marking for the LYNX™, the world's first and only pattern scanning laser indirect ophthalmoscope (LIO). This innovative device not only promises to revolutionize the way ophthalmologists conduct examinations but also enables unprecedented flexibility and mobility within the clinical setting.

The Innovation Behind LYNX™

On January 27, 2025, Norlase announced the immediate commercial launch of LYNX™, which integrates advanced laser technology and pattern scanning capabilities into a lightweight headset design. The device is battery-powered, enhancing portability and allowing ophthalmologists to perform examinations virtually anywhere without the limitations of traditional equipment.

Norlase CEO Oliver Hvidt stated, "Time is the most precious commodity for modern ophthalmologists. With the introduction of LYNX™, we are addressing a long-standing demand for a laser indirect ophthalmoscope with pattern scanning functionality. This device not only reduces the ergonomic burden on doctors but also enhances the quality time they can spend with patients."

Key Features of LYNX™

1. Integrated Design: The laser, scanner, and beam accuracy system are fully embedded within an ultra-lightweight headset.
2. Battery Operation: The device runs on batteries, ensuring flexibility and mobility during examinations.
3. Diverse Pattern Options: LYNX™ offers a full range of patterns, including grid configurations from 2x2 to 5x5, triple arcs, and circles.
4. Superior Visualization: Equipped with simplyCLEAR safety filters for enhanced clarity.
5. Multilingual Voice Control: Users can effortlessly adjust patterns and parameters using voice commands.

Dr. Daniel Diaz from the Retina Consultants clinic in Miami expressed his enthusiasm for the LYNX™, saying, “This innovative device combines the speed and efficiency of laser technology with unmatched portability and comfort, setting a new standard for indirect laser examinations.” His comments echo the positive feedback from initial users who have hailed the LYNX™ as a significant advancement in retinal treatment.

A Commitment to Innovation

Norlase has consistently pushed the envelope in ophthalmic technology, with LYNX™ being their fourth product launched in just five years. Each product, from the LEAF, an ultra-compact laser photocoagulator, to the ECHO, the-first ultra-portable pattern scanning laser, exemplifies Norlase's dedication to enhancing the practice of ophthalmology.

Founded in Denmark, Norlase consists of global experts in ophthalmology, laser technology, and medical device development. Their mission is to improve clinical efficiency, patient care, and the comfort of ophthalmologists worldwide. Aside from LYNX™, Norlase's portfolio includes:

• - LEAF: A laser photocoagulator that is ten times smaller than existing systems, directly attachable to slit lamps.
• - LION: The first fully integrated green laser with an indirect laser ophthalmoscope.
• - ECHO: The first ultra-portable laser for pattern scanning.

For more information about LYNX™ and Norlase's family of products, visit norlase.com.

Conclusion

The launch of the LYNX™ represents a significant leap forward in ophthalmic technology, providing eye care professionals with an innovative tool that enhances both efficiency and patient interaction. As Norlase continues to lead the way in cutting-edge ophthalmological solutions, patients and doctors alike will benefit from these advancements in their ongoing vision care journey.